Rhizen Pharmaceuticals S.A.
Records under this name other than the patents Rhizen Pharmaceuticals S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 21 patents it holds.
Back to Rhizen Pharmaceuticals S.A.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,072,013 | Novel Selective PI3K Delta Inhibitors Lapsed on the fee record Ended Sep 11, 2026 · High confidence | Lapsed on the fee record | Ended Sep 11, 2026 | High confidence |
| US 10,058,539 | Pharmaceutical Compositions Containing a PDE4 Inhibitor and a PI3 Delta or Dual PI3 Delta-Gamma Kinase Inhibitor Lapsed on the fee record Ended Aug 28, 2026 · High confidence | Lapsed on the fee record | Ended Aug 28, 2026 | High confidence |
| US 11,352,359 | PI3K protein kinase inhibitors Lapsed on the fee record Ended Jun 7, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 7, 2026 | From the USPTO record |
| US 9,969,740 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations Lapsed on the fee record Ended May 15, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 15, 2026 | From the USPTO record |
| US 9,944,631 | Modulators of calcium release-activated calcium channel Lapsed on the fee record Ended Apr 17, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 17, 2026 | From the USPTO record |
| US 9,815,831 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases Lapsed on the fee record Ended Nov 14, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 14, 2025 | From the USPTO record |
| US 9,783,533 | Glutaminase inhibitors Lapsed on the fee record Ended Oct 10, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 10, 2025 | From the USPTO record |
| US 9,775,841 | Compounds as modulators of protein kinases Lapsed on the fee record Ended Oct 3, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 3, 2025 | From the USPTO record |
| US 9,737,521 | Pharmaceutical Compositions Containing a PDE4 Inhibitor and a PI3 Delta or Dual PI3 Delta-Gamma Kinase Inhibitor Lapsed on the fee record Ended Aug 22, 2025 · High confidence | Lapsed on the fee record | Ended Aug 22, 2025 | High confidence |
| US 11,065,236 | Pharmaceutical Compositions Containing a PDE4 Inhibitor and a P13 Delta or Dual P13 Delta-Gamma Kinase Inhibitor Lapsed on the fee record Ended Jul 20, 2025 · High confidence | Lapsed on the fee record | Ended Jul 20, 2025 | High confidence |